Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465448 | 0.95 | PARP1 (0.48) | PARP1SMYD3HSD17B10KDRTP53 | |
| SCHEMBL5470024 | 0.86 | PARP1 (0.58) | PARP1SMYD3HSD17B10KDR | |
| SCHEMBL5472591 | 0.83 | PARP1 (0.49) | PARP1SMYD3HSD17B10KDRTP53 | |
| Hydrochloric Acid SCHEMBL5465703 | 0.80 | TAS1R3 (0.34) | POLBSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL5465466 | 0.80 | PARP1 (0.44) | PARP1SMYD3HSD17B10KDRTP53 | |
| SCHEMBL5458536 | 0.79 | SMYD3 (0.49) | PARP1SMYD3HSD17B10KDRTP53 | |
| SCHEMBL5466891 | 0.79 | PARP1 (0.53) | PARP1SMYD3TP53POLBSMN1; SMN2 | |
| SCHEMBL5471766 | 0.78 | PARP1 (0.51) | PARP1SMYD3HSD17B10KDRTP53 | |
| SCHEMBL5465443 | 0.78 | PARP1 (0.56) | PARP1SMYD3KDRTP53POLB | |
| SCHEMBL5458528 | 0.77 | PARP1 (0.55) | PARP1SMYD3KDRTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049583-A1 | Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | US | disclosed |
| US-7141566-B1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049583-A1 | Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents | CYP3A5, XDH, CYP4Z1 | PARP1 2890/4885SMYD3 4613/4885HSD17B10 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.